Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015 |
| December 11, 2018 | December 2018 Bond Updates |
|
LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate... |
| View more at: https://www.prnewswire.com:443/news-releases/alligator-bioscience-starts-clinical-phase-i-study-with-ator-1015-300763190.html |
| Related News |
|